Tivoli A/S
Tivoli increase expectations following a historic Halloween and solid to the Christmas season
Tivoli increase expectations following a historic Halloween and solid to the Christmas season
Tivoli's Christmas season started on November 15th and has so far been well-visited by guests from both home and abroad. Tivoli's Christmas market has been ranked as one of the world's most beautiful Christmas markets, and Tivoli looks forward to a splendid end to 2024, which will mark a very special year for Tivoli. The recently concluded Halloween season ended with record-breaking revenue and earnings, and this, combined with the solid start to the Christmas season, makes Tivoli increase its expectations for the year’s financial results.
Tivoli's most recently announced expectations for 2024 were a revenue of around DKK 1,250 million and a profit before tax of around DKK 130 million. With this increase, Tivoli now expects a revenue of around DKK 1,300 million and a profit before tax of around DKK 150 million.
”Tivoli's seasons are well-visited, and guests spend both time and money when they visit the Gardens. Tivoli's business is strong, which means that Tivoli is now looking at a profit before tax of approximately DKK 150 million, which is historically high. We look forward to the beautiful Christmas season bringing joy to both young and old throughout December and actually all the way until January 5th” says CEO, Susanne Mørch Koch.
Best regards,
Tom Knutzen Susanne Mørch Koch
Chairman CEO
Contact person: Head of press, Torben Plank phone 22237440 / tpl@tivoli.dk
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG25.4.2025 22:05:00 CEST | Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
T-knife Therapeutics25.4.2025 19:00:00 CEST | Press release
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
Zymeworks Inc.25.4.2025 19:00:00 CEST | Press release
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Sequana Medical NV25.4.2025 18:00:00 CEST | Press release
Press release: Transparency Notification from Shareholders
Sanoma Corp25.4.2025 17:30:00 CEST | Press release
SANOMA CORPORATION: ACQUISITION OF OWN SHARES 25 April 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom